Last reviewed · How we verify
Eribulin biweekly regimen
Eribulin is a microtubule dynamics inhibitor that binds to tubulin and disrupts microtubule formation, leading to cancer cell death.
Eribulin is a microtubule dynamics inhibitor that binds to tubulin and disrupts microtubule formation, leading to cancer cell death. Used for Metastatic breast cancer, Liposarcoma, Other advanced solid tumors (in clinical development).
At a glance
| Generic name | Eribulin biweekly regimen |
|---|---|
| Sponsor | Ma Fei，MD |
| Drug class | Microtubule inhibitor |
| Target | Tubulin / Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Eribulin is a non-taxane microtubule inhibitor that suppresses microtubule growth dynamics by binding to the plus end of microtubules. This disruption of microtubule dynamics impairs mitotic spindle formation and triggers apoptosis in cancer cells. The biweekly regimen refers to the dosing schedule of administration every two weeks.
Approved indications
- Metastatic breast cancer
- Liposarcoma
- Other advanced solid tumors (in clinical development)
Common side effects
- Neutropenia
- Peripheral neuropathy
- Fatigue
- Nausea
- Alopecia
- Anemia
- Diarrhea
Key clinical trials
- Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial (PHASE3)
- Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |